Fennec Pharmaceuticals (FENC) Equity Average (2011 - 2025)
Fennec Pharmaceuticals posted quarterly Equity Average of $15.5 million for Q4 2025, up 380.54% year-on-year from $3.2 million in Q4 2024, and up 359.14% on a QoQ basis from -$6.0 million in Q3 2025.
Fennec Pharmaceuticals (FENC) has 15 years of Equity Average data on file, last reported at $15.5 million in Q4 2025.
- For the quarter ending Q4 2025, Equity Average rose 380.54% year-over-year to $15.5 million; the trailing twelve-month figure through Dec 2025 stood at $15.5 million (up 380.54% YoY), and the FY2025 full-year result was $14.8 million, up 269.2% from the prior year.
- Equity Average for Q4 2025 stood at $15.5 million, up from -$6.0 million in the prior quarter.
- Across five years, Equity Average topped out at $27.0 million in Q1 2021 and bottomed at -$11.1 million in Q4 2023.
- The 5-year median for Equity Average is -$1.6 million (2022), against an average of $3.5 million.
- The widest annual swing landed in 2023, when Equity Average tumbled 9607.73%; it then jumped 380.54% in 2025.
- A 5-year view of Equity Average shows it stood at $17.4 million in 2021, then sank by 99.33% to $116500.0 in 2022, then sank by 9607.73% to -$11.1 million in 2023, then soared by 50.15% to -$5.5 million in 2024, then surged by 380.54% to $15.5 million in 2025.
- The last three Equity Average figures came in at $15.5 million (Q4 2025), -$6.0 million (Q3 2025), and -$6.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn | 15.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.49 Mn |
| Sep 30, 2025 | -5.98 Mn |
| Jun 30, 2025 | -6.67 Mn |
| Mar 31, 2025 | -5.88 Mn |
| Dec 31, 2024 | -5.52 Mn |
| Sep 30, 2024 | -3.26 Mn |
| Jun 30, 2024 | 828,500.00 |
| Mar 31, 2024 | -4.30 Mn |
| Dec 31, 2023 | -11.08 Mn |
| Sep 30, 2023 | -10.13 Mn |
| Jun 30, 2023 | -8.53 Mn |
| Mar 31, 2023 | -4.95 Mn |
| Dec 31, 2022 | 116,500.00 |
| Sep 30, 2022 | 5.67 Mn |
| Jun 30, 2022 | 10.53 Mn |
| Mar 31, 2022 | 14.15 Mn |
| Dec 31, 2021 | 17.39 Mn |
| Sep 30, 2021 | 20.65 Mn |
| Jun 30, 2021 | 23.61 Mn |
| Mar 31, 2021 | 27.00 Mn |
| Dec 31, 2020 | 30.13 Mn |
| Sep 30, 2020 | 33.66 Mn |
| Jun 30, 2020 | 22.29 Mn |
| Mar 31, 2020 | 10.17 Mn |
| Dec 31, 2019 | 13.44 Mn |
| Sep 30, 2019 | 15.74 Mn |
| Jun 30, 2019 | 17.84 Mn |
| Mar 31, 2019 | 20.26 Mn |
| Dec 31, 2018 | 22.09 Mn |
| Sep 30, 2018 | 23.86 Mn |
| Jun 30, 2018 | 25.26 Mn |
| Mar 31, 2018 | 26.21 Mn |
| Dec 31, 2017 | 17.81 Mn |
| Sep 30, 2017 | 9.27 Mn |
| Jun 30, 2017 | 6.27 Mn |
| Mar 31, 2017 | 3.22 Mn |
| Dec 31, 2016 | 3.90 Mn |
| Sep 30, 2016 | 4.44 Mn |
| Jun 30, 2016 | 2.45 Mn |
| Mar 31, 2016 | 395,500.00 |
| Dec 31, 2015 | 783,500.00 |
| Sep 30, 2015 | 1.07 Mn |
| Jun 30, 2015 | 969,000.00 |
| Mar 31, 2015 | 719,500.00 |
| Dec 31, 2014 | -1.31 Mn |
| Sep 30, 2014 | -3.94 Mn |
| Jun 30, 2014 | -4.50 Mn |
| Mar 31, 2014 | -2.89 Mn |
| Dec 31, 2013 | -2.79 Mn |
| Sep 30, 2013 | -3.28 Mn |
| Jun 30, 2013 | -5.75 Mn |
| Mar 31, 2013 | -7.01 Mn |
| Dec 31, 2012 | -1.84 Mn |
| Sep 30, 2012 | 1.66 Mn |
| Jun 30, 2012 | 2.32 Mn |
| Mar 31, 2012 | 1.24 Mn |
| Dec 31, 2011 | -1.90 Mn |
| Sep 30, 2011 | -2.18 Mn |
| Jun 30, 2011 | -483,500.00 |
| Mar 31, 2011 | -2.60 Mn |